Biotech and Pharmaceuticals Biotechnology

More

  • Biotech bubble formation? Friday, 14 Mar 2014 | 12:46 PM ET
    Biotech bubble formation?

    CNBC's Bertha Coombs discusses potential froth in the biotech sector due to an uptick in biotechnology IPOs.

  • XBI is 'best way to biotech': Trader Wednesday, 12 Mar 2014 | 12:45 PM ET
    XBI is 'best way to biotech': Trader

    FMHR traders Mike Murphy and Pete Najarian debate the play on the S&P biotech ETF.

  • Believe in strong Europe reimbursement: Dendreon CEO Wednesday, 5 Mar 2014 | 5:29 PM ET
    Believe in strong Europe reimbursement: Dendreon CEO

    Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.

  • Buy Regeneron today: Pro Wednesday, 5 Mar 2014 | 2:40 PM ET
    Buy Regeneron today: Pro

    Sam Isaly of OrbiMed Advisors, explains why he likes the new products of Regeneron, and why he expects Intermune to go higher.

  • Hot health care trades Tuesday, 25 Feb 2014 | 12:15 PM ET
    Hot health care trades

    CNBC's Bertha Coombs reports on which sectors and stocks are impacted by Obamacare, and the FMHR traders share their top health care stock picks.

  • Best biotech stock plays Thursday, 20 Feb 2014 | 2:40 PM ET
    Best biotech stock plays

    Barbara Ryan, FTI Consulting managing director, analyzes the biotech sector and reveals which companies are on the forefront of therapies worth investing in.

  • Pharma for man's best friend Monday, 10 Feb 2014 | 3:17 PM ET
    Pharma for man's best friend

    Steven St. Peter, Aratana Therapeutics president & CEO, discusses the need for pet medical pharmaceuticals and the market for pet insurance.

  • Biotech boom keeps going Wednesday, 29 Jan 2014 | 1:45 PM ET
    Biotech boom keeps going

    CNBC's Sheila Dharmarajan reports on what factors contribute to the biotech sector outperforming this year.

  • Bristol-Myers Squibb performance was staggering: Analyst

    As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.

  • Biotech: 2014's favored child Thursday, 16 Jan 2014 | 12:15 PM ET
    Biotech: 2014's favored child

    Mark Schoenebaum, ISI Group analyst, breaks down the red hot biotech sector and explains why Gilead Sciences is his best play.

  • Twitter almost impossible to value: Analyst Tuesday, 14 Jan 2014 | 10:50 AM ET
    Twitter almost impossible to value: Analyst

    Dan Fitzpatrick, StockmarketMentor.com president & technical analyst, takes a look at the charts to get a technical read on Twitter. Also a look at why Fitzpatrick likes the biotech sector.

  • Alexandria CEO: Real estate a long-term play Monday, 13 Jan 2014 | 2:38 PM ET
    Alexandria CEO: Real estate a long-term play

    Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss its firm's success, and how rising yields impact its dividend.

  • Alexandria CEO: Top tenants looking for more space Monday, 13 Jan 2014 | 2:36 PM ET
    Alexandria CEO: Top tenants looking for more space

    Alexandria Real Estate Equities founder, chairman and CEO Joel Marcus discuss real estate demand in the biotech industry.

  • Perrigo CEO: Got to get our name out Monday, 13 Jan 2014 | 2:24 PM ET
    Perrigo CEO: Got to get our name out

    Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.

  • Perrigo CEO: Elan purchase lowers tax rate Monday, 13 Jan 2014 | 2:24 PM ET
    Perrigo CEO: Elan purchase lowers tax rate

    Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.

  • Biogen CEO: More products, company is focused Monday, 13 Jan 2014 | 2:15 PM ET
    Biogen CEO: More products, company is focused

    Biogen Idec CEO George Scangos discusses the busy year ahead for the company, including the EU launch of Tecfidera and when a dividend will be offered.

  • Monsanto wins high court challenge on seed patents Monday, 13 Jan 2014 | 2:06 PM ET
    A protester against Monsanto genetically modified food in New York's Bryant Park.

    The Supreme Court upheld Monsanto's biotech seed patents on Monday, dealing a blow to organic farmers and critics of the company.

  • Roche now world leader in cancer treatment: Pro Friday, 10 Jan 2014 | 2:45 PM ET
    Roche now world leader in cancer treatment: Pro

    The outlook for biotech is "wonderful," explains Sam Isaly, Orbimed Advisors managing partner.

  • Intercept's drug could do billions a year: Analyst Friday, 10 Jan 2014 | 2:42 PM ET
    Intercept's drug could do billions a year: Analyst

    Shares of Intercept Pharmaceuticals are up more than 560 percent this week alone. Akiva Felt, Oppenheimer senior analyst, shares his optimistic view for the company.

  • Singapore growth going to hold up: Pro Wednesday, 1 Jan 2014 | 9:51 PM ET
    Singapore Growth Going To Be OK: Pro

    Daryl Liew, Head Of Portfolio Management of REYL Singapore advises investors to look past short-term volatilities in the country's economy after Q4 GDP data missed expectations